DOC/P
Bi-weekly
(n=170)
DOC/P
3-weekly
(n=169)
p
TTTF (median)
5.6 mo
4.9 mo
0.014
OS (median)
19.5 mo
17 mo
0.021
PSA response
49%
42%
0.49
Clinical response
- CR or PR
- Stable
- Progression
23%
46%
8%
22%
46%
11%
0.95
DOC/P
Bi-weekly
(n=170)
DOC/P
3-weekly
(n=169)
Hematological
- Neutropenia
- Leucopenia
- Anemia
- Thrombocytopenia
- Febrile neutropenia
36%
13%
1%
1%
4%
53%
29%
1%
0
14%
Non-hematological
-
Fatigue
-
Infection without
neutropenia
-
Neutropenic
15%
11%
6%
15%
12%
24%
Kellokumpu-Lehtinen P et al. Lancet Oncol 2013;14:117–24
Docetaxel bi-weekly (PROSTY)
Less hematological toxicity
Randomized phase III trial comparing DOC 75mg/m
2
every 3 weeks
vs DOC 50mg/m
2
every 2 weeks
SAEU.CAB.16.07.0040j
